Sound waves used to sneak medicine into brain for ALS

NCT ID NCT07193953

Ongoing Disease control Sponsor: Sunnybrook Health Sciences Centre Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 15, 2026 · Updated 3 times

Summary

This early-stage trial tests whether a special helmet that uses focused ultrasound can safely open the blood-brain barrier to deliver an anti-inflammatory drug (IVIg) directly to the motor cortex in people with ALS. Six participants will receive two doses of IVIg, with the second dose combined with the ultrasound procedure. The main goals are to check safety and see if the drug reaches its target.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Intravenous immunoglobulin (IVIg)
What this could lead to: If this works, it could show a new way to deliver treatments to the brain for ALS, potentially reducing inflammation and slowing disease progression.
What could go wrong: This is a very early phase 1 trial with only 6 people. It focuses on safety, not effectiveness. The procedure involves opening the blood-brain barrier, which carries risks like bleeding or swelling.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis motor neuron disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALS AMYOTROPHIC LATERAL SCLEROSIS

Contacts and locations

Locations

Sunnybrook Health Sciences Centre

Toronto, Ontario, M4N 3M5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.